Mersana Therapeutics, INC Form 4 insider transactions

Andrew Hack, a director of Mersana Therapeutics, Inc., disposed of all his direct and indirect common stock and stock options following the company's merger with Day One Biopharmaceuticals, Inc.

Mersana Therapeutics director Kristen Hege reported the disposition of all her common stock and stock options following the company's merger with Day One Biopharmaceuticals.

Mersana Therapeutics Director Allene Diaz disposed of all common stock and options following the company's merger with Day One Biopharmaceuticals.

Mersana Therapeutics, Inc. has been acquired by Day One Biopharmaceuticals, Inc., with Director Willard H. Dere reporting the disposition of his common stock and stock options as part of the merger.

Mersana Therapeutics, Inc. completed its merger with Day One Biopharmaceuticals, Inc., converting executive Alejandra Carvajal's equity holdings into cash and contingent value rights.

Mohan Bala, SVP of Mersana Therapeutics, reported the disposition of all his common stock, stock options, and restricted stock units following the company's merger with Day One Biopharmaceuticals.

Mersana Therapeutics director Lawrence M. Alleva reports changes in beneficial ownership following the company's merger with Day One Biopharmaceuticals, including cash-out of shares and options.

Mersana Therapeutics CEO Martin H. Huber Jr. disposed of all common stock, stock options, and restricted stock units following the company's merger with Day One Biopharmaceuticals.

Mersana Therapeutics, Inc. has been acquired by Day One Biopharmaceuticals, Inc., resulting in the conversion of executive Ashish Mandelia's equity holdings into cash and contingent value rights.

Mersana Therapeutics Director Anna Protopapas reports the disposition of all her company securities following the completion of its acquisition by Day One Biopharmaceuticals.

Mersana Therapeutics, Inc. completed its merger with Day One Biopharmaceuticals, Inc., converting executive Timothy B Lowinger's equity holdings into cash and contingent value rights.

Mersana Therapeutics Director David Mott reported the disposition of common stock and stock options following the company's merger with Day One Biopharmaceuticals, effective January 6, 2026.

Mersana Therapeutics' SVP, COO & CFO, Brian DeSchuytner, reported the disposition of common stock, stock options, and restricted stock units following the company's merger with Day One Biopharmaceuticals.

Mersana Therapeutics' SVP, Chief Development Officer, Mohan Bala, reported the vesting of restricted stock units and a subsequent sale of shares for tax obligations.

Mersana Therapeutics CEO Martin H. Huber Jr. reported the vesting of restricted stock units and a subsequent tax-related sale of common stock under a Rule 10b5-1 plan.

Mersana Therapeutics, Inc. Director Lawrence M. Alleva acquired 61,500 stock options with an exercise price of $0.36, vesting on the earlier of the first anniversary of the grant date or the 2026 Annual Meeting.

Mersana Therapeutics, Inc. director Andrew A. F. Hack was granted 61,500 stock options with an exercise price of $0.36, aligning his interests with the company's performance.

Mersana Therapeutics, Inc. Director Willard H. Dere was granted 61,500 stock options with an exercise price of $0.36, vesting over the next year.

Mersana Therapeutics, Inc. has granted 61,500 stock options to Director Allene M. Diaz, with an exercise price of $0.36 per share, vesting on the earlier of June 12, 2026, or the 2026 Annual Meeting of Stockholders.

Mersana Therapeutics, Inc. Director Anna Protopapas has been granted 61,500 stock options with an exercise price of $0.36 per share, aligning her interests with the company's long-term performance.

Mersana Therapeutics, Inc. Director Kristen Hege has reported the acquisition of 61,500 stock options with an exercise price of $0.36, vesting over the next year.

Mersana Therapeutics, Inc. Director David M. Mott has been granted 61,500 stock options with an exercise price of $0.36, signaling potential insider confidence.

Mersana Therapeutics' VP, Chief Accounting Officer, Ashish Mandelia, executed multiple transactions involving company stock, including the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Director Anna Protopapas of Mersana Therapeutics sold shares to cover tax obligations after restricted stock units vested, while also holding shares through family trusts.

Mersana Therapeutics' SVP, Chief Sci.&Tech. Officer, Timothy B. Lowinger, exercised stock options and sold shares to cover tax obligations, according to a recent SEC filing.

Mersana Therapeutics CEO, Martin H. Huber Jr., exercised stock options and sold shares to cover tax obligations related to vesting restricted stock units.

Brian DeSchuytner, SVP, COO & CFO of Mersana Therapeutics, exercised stock options and sold shares to cover tax obligations related to vesting restricted stock units.

Alejandra Carvajal, SVP and Chief Legal Officer at Mersana Therapeutics, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Mersana Therapeutics' SVP, Chief Development Officer, Mohan Bala, exercised stock options and sold shares to cover tax obligations, according to a recent SEC filing.

Director Anna Protopapas of Mersana Therapeutics reports acquiring shares through RSU vesting and selling some to cover tax obligations.